Boston Sci prevails in lawsuit over sales group

Boston Scientific ($BSX) has scored a win in a Boston court with the dismissal of a class-action lawsuit alleging it had failed to disclose questionable sales practices to investors. The decision comes a year after four pension funds filed suit claiming they had lost more than $2.8 million from buying the company's stock at an artificially inflated price. In his decision, U.S. District Judge Douglas Woodlock said the pension funds' complaint failed to state a "cognizable" claim for securities fraud, Bloomberg notes. Story 

Suggested Articles

The FDA has authorized its first COVID-19 antibody test for use in doctors' offices, urgent care centers and emergency rooms.

The clinical testing giant LabCorp will now begin rolling out a blood test for lung cancer developed by Resolution Bioscience.

Cognoa aims to equip pediatricians with an AI-powered app that can spot the signs of autism, allowing them to diagnose in the doctor's office.